BioSpace News Archive

Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.

Adamis Pharmaceuticals Corporation announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has received a written notification from the Nasdaq Stock Market LLC dated May 9, 2023 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares set forth in the Nasdaq Rules for continued Nasdaq listing.

Lucid Diagnostics Inc. today provided a business update for the Company and presented financial results for the three months ended March 31, 2023.

Clinical Laserthermia Systems Americas, Inc., a leading provider of office-based, focal laser ablation systems for urologists, announced that AVANT Concierge Urology of Winter Garden, FL, has safely treated its first patients with low-to- intermediate risk prostate cancer using its TRANBERG™ Thermal Therapy System.

BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) today published its financial results for the first quarter ended March 31, 2023, and provided a business update.

Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

9 Meters Biopharma, Inc., a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, provided a business update and announced financial results for the first quarter ended March 31, 2023.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will participate in the William Blair 43rd Annual Growth Stock Conference.

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient has been dosed in a Phase I trial of the company’s oncolytic adenovirus TILT-123.